Explore

Trendline Trendline
Arrowhead Pharmaceuticals Advances RNAi Therapeutics with New Clinical Trials and Financial Growth

Arrowhead Pharmaceuticals Advances RNAi Therapeutics with New Clinical Trials and Financial Growth

Arrowhead Pharmaceuticals Advances RNAi Therapeutics with New Clinical Trials and Financial Growth
Rapid Read Rapid Read
New Cholesterol-Lowering Pill Enlicitide Shows Promising Results in Clinical Trial

New Cholesterol-Lowering Pill Enlicitide Shows Promising Results in Clinical Trial

A new experimental pill, enlicitide, has demonstrated significant potential in reducing artery-clogging cholesterol levels in patients who are at high risk of heart attacks, despite already taking statins. According to a study published in the New England Journal of Medicine, enlicitide was tested on over 2,900 high-risk patients, resulting in a reduction of LDL cholesterol by up to 60% over six months. This pill offers an alternative to the current PCSK9 inhibitor injections, which are less favored due to their complexity and the discomfort of administration. The study, funded by Merck, indicates that enlicitide could become a more accessible option for patients if approved by the U.S. Food and Drug Administration (FDA). The FDA has already included the drug in a program for ultra-fast reviews, suggesting a potential for quicker availability to the public.
Discover daily Discover daily
How Scientists Build Custom Peptides Using "Solid-Phase" Synthesis

How Scientists Build Custom Peptides Using "Solid-Phase" Synthesis

Peptide synthesis is a fundamental process in organic chemistry, enabling the production of peptides, which are compounds where multiple amino acid...
Discover daily Discover daily
Peptides Explained: How These Tiny Molecules Drive Everything from Hormones to Antibiotics

Peptides Explained: How These Tiny Molecules Drive Everything from Hormones to Antibiotics

Peptides are fascinating molecules that serve a multitude of functions in biological systems. These short chains of amino acids are not only the bu...
Trendline Trendline
Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials
Trendline Trendline
Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials
Rapid Read Rapid Read
Boehringer Ingelheim Receives FDA Emergency Use Authorization for IVOMEC to Combat New World Screwworm in Cattle

Boehringer Ingelheim Receives FDA Emergency Use Authorization for IVOMEC to Combat New World Screwworm in Cattle

Boehringer Ingelheim has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for its IVOMEC (ivermectin) 1% Injection. This authorization allows the use of the injection to prevent infestations caused by the New World screwworm (NWS) in cattle. The NWS is a parasitic fly whose larvae can cause severe tissue damage and potentially fatal infestations in warm-blooded animals. Although the NWS is not currently present in the United States, recent cases have been reported in northern Mexico, particularly in Tamaulipas, a state bordering Texas. The EUA permits the use of IVOMEC for cattle within 24 hours of birth, during castration, or when a wound appears, except for female dairy cattle producing milk for human consumption and calves intended for veal. This is the first EUA for an over-the-counter drug aimed at preventing NWS infestations in cattle.
Trendline Trendline
Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy

Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy

Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy
Trendline Trendline
Immuneering's New Cancer Drug Focuses on Quality of Life for Patients

Immuneering's New Cancer Drug Focuses on Quality of Life for Patients

Immuneering's New Cancer Drug Focuses on Quality of Life for Patients
Rapid Read Rapid Read
Experimental Cholesterol-Lowering Pill Shows Promise for High-Risk Patients

Experimental Cholesterol-Lowering Pill Shows Promise for High-Risk Patients

A new experimental pill, enlicitide, has demonstrated significant potential in reducing artery-clogging cholesterol in patients at high risk of heart attacks, according to recent research. The pill, which is still under investigation, offers a novel approach to cholesterol management by helping the body eliminate cholesterol, a process currently achievable only through injectable medications. In a study involving over 2,900 high-risk patients, those who took enlicitide alongside their standard treatment saw their LDL cholesterol levels drop by up to 60% over six months. This reduction is comparable to that achieved by PCSK9 inhibitors, which are injectable drugs. The study, funded by Merck, provides crucial data for seeking FDA approval, with the agency promising an expedited review process.
Trendline Trendline
Eli Lilly Discontinues Three Therapies Amid GLP-1 Expansion Strategy

Eli Lilly Discontinues Three Therapies Amid GLP-1 Expansion Strategy

Eli Lilly Discontinues Three Therapies Amid GLP-1 Expansion Strategy
Rapid Read Rapid Read
NYU Langone Researchers Identify Brain Region for One-Shot Learning, Impacting AI Development

NYU Langone Researchers Identify Brain Region for One-Shot Learning, Impacting AI Development

Researchers at NYU Langone Health have identified the high-level visual cortex (HLVC) as the brain region responsible for 'one-shot learning,' a process where a single exposure to an image significantly enhances recognition ability. This discovery, published in Nature Communications, highlights how stored images, or 'priors,' are accessed in the HLVC to facilitate this rapid learning. The study involved using functional magnetic resonance imaging (fMRI) and intracranial electroencephalography (EEG) to track brain activity during image recognition tasks. The findings suggest that the HLVC plays a crucial role in accessing these priors, which are essential for recognizing blurred or partially obscured images. This research also connects to conditions like schizophrenia and Parkinson's disease, where abnormal one-shot learning can lead to hallucinations.